GONADORELIN

Sexual Function & LibidoPrescription Available

FDA-approved with legitimate clinical applications, though most research focuses on fertility and menstrual disorders rather than the post-cycle therapy protocols it's commonly associated with in research communities.

Primarily studied by reproductive endocrinologists and fertility researchers, with growing interest in post-cycle therapy protocols among performance enhancement research communities.

FDA Status

FDA Approved

Since Feb 2026

Evidence

Strong

Studies

30 total, 1 human

What is GONADORELIN?

This synthetic version of the brain's natural gonadotropin-releasing hormone has carved out a niche in hormone restoration research, particularly among bodybuilders and athletes looking to restart their natural testosterone production after steroid cycles. Unlike direct testosterone replacement, gonadorelin works by essentially reminding the pituitary gland to do its job. Clinically, it's also used in fertility treatments and certain hormonal disorders.

When administered, gonadorelin travels to specific receptors in the anterior pituitary gland, where it acts like a molecular alarm clock, prompting the release of two key hormones: luteinizing hormone and follicle-stimulating hormone. These hormones then signal the testes to produce testosterone naturally, rather than supplying testosterone from an external source. Think of it as restarting your body's own hormone factory instead of importing hormones from outside.

What the Research Shows

The 30-study dataset is misleading since the evidence summary indicates only 1 human study despite claiming 27 human studies, with just 4 randomized controlled trials providing limited comparative data.

Of 30 total studies (27 human studies, 4 RCTs), gonadorelin demonstrated effects on hormone regulation and erythropoiesis, though the evidence base appears primarily observational with limited randomized controlled trial data. Key applications examined included menorrhagia management (where gonadorelin was evaluated alongside NSAIDs, progestogens, and danazol) and breast pain treatment, though comparative efficacy data from the RCT subset was not detailed in the available outcomes.